explore -WSS

explore

author：knowledge 2025-09-29 22:52:28 - browse：9

In a lab at Harvard Medical School, Professor David A. Sinclair looks into the camera from behind a row of bottles — coverage from STAT — David Sinclair in his lab at Harvard Medical School. Craig F. Walker/Globe Staff

Renowned Harvard University geneticist and longevity researcher David Sinclair recently made an astonishing assertion: Scientists had developed the first pill — well, a soft, beef-flavored chew — “proven to reverse aging” in dogs. Which miracle molecules delivered this supposed scientific breakthrough, he didn’t say. But he told his 438,000 followers on X where they could buy it: the website of Animal Bioscience, a veterinary supplement company he founded and which is headed by his brother, Nick Sinclair.

The claim in a company news release, followed by the tweet stating that the supplement was “proven to slow the effects of aging,” has sparked outrage from other scientists online, and the board of an international organization of top longevity researchers — which David Sinclair leads — will discuss the matter at its meeting this week.

Despite his enthusiasm, there is no published scientific research that has yet demonstrated the compounds in Animal Bioscience’s supplements — which have been on the market for more than a year — reverse or even slow aging in dogs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： A solution to the after

focus

entertainment

WSS

What to make of Biden’s latest efforts on cancer research

With competition flaring, obesity drug hits goal in liver disease study

A new nitrogen execution bill also undermines medical licensing

Food makers tried to stack nutrition panel with preferred experts

IRA could hurt research into orphan drugs for rare diseases

PEPFAR is under serious threat — and so is global health

hotspot

explore

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Cancer drug shortages should be causing more outrage

Popular nasal decongestant doesn't actually relieve congestion

As demand for Covid shots wanes, Moderna seeks its next success

Acelyrin, a rare IPO success, stumbles in its first big test

Novavax promises a turnaround & Lilly roils the obesity market

New documents shed light on MD Anderson Cancer Institute feud

https://cbu01.alicdn.com/img/ibank/2016/133/987/3385789331_1838463022.220x220xz.jpg

Obesity drugs seen as possible treatment for liver disease MASH

hotspot

Private equity could exacerbate cardiology's overuse problem, experts fear

Diverse clinical trials: Why aren’t we there yet?

FDA approves updated Covid vaccines

He's a Nobel laureate. Critics say he was misleading on Covid

A solution to the after

Private equity could exacerbate cardiology's overuse problem, experts fear

hotspot

focus

entertainment

hotspot